Pressure Biosciences PBIO Stock News

Pressure Biosciences Inc (OTCMKTS: PBIO) is a stock that should be on your watchlist this morning as a slew of news starts to hit the tape. Just yesterday, the company announced plans to acquire Cannaworx. Today, the excitement among investors is likely to continue with news of yet another planned acquisition breaking.

PBIO Stock Could Be A Big Play On SkinScience Labs Acquisition

In the press release, Pressure BioSciences said that it plans on acquiring SkinScience Labs. The company said that it has entered into a letter of intent with the company, which so happens to be the parent company of the award-winning Dr. Denese skin care and anti-aging product lines.

In the release, the company said that the acquisition will take place through Cannaworx, the company that PBIO said it would be taking over yesterday.

The company also said that moving forward, the Dr. Denese SkinScience product lines will liverage its Ultra Shear Technology, also known as UST. This will help to improve the quality of these already high-quality products.

In a statement, Mr. Richard T. Schumacher, President and CEO at PBIO, had the following to offer:

The Dr. Denese SkinScience brand has reached top performing status on QVC for a skin care line, selling over 25 million units and receiving multiple QVC customer choice beauty awards. Adrienne’s tremendous brand recognition, regularly repeating customer base, and major existing sales momentum brings immediate accretive impact into the PBI portfolio – and we know that our UST nanoemulsions will create powerful new leverage and opportunities for her expanding product lines. Our team has worked very hard to bring this pivotal transition together for PBI and its shareholders, and we are very excited about the prospects for growth and value appreciation in our combined companies going forward.

Why This Is Such Big News

It’s clear that Pressure Biosciences is making big moves at the moment. First and foremost, Dr. Adrienne Denese is an industry leader in the field of scientific skin care breakthrough tech. She is an accomplished doctor, businesswoman, and skin care visionary, and this aquicition brings her expertise to the company.

Not to mention, the products involved in the acquisition have the potential to be blockbusters. In fact, over the past 17 years, these products have been top sellers on QVC. In 2018, $18 million worth of these products were sold bringing total sales to more than $500 million over the past 17 years.

The bottom line here is that PBIO is using its proprietary technology to take an already strong line of products and make it better. That should earn the stock some serious attention.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Get Free Alerts

Join our free mailing list to receive stock alerts!

This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Pressure Biosciences, CNA Finance has been hired to develop and publicly disseminate information about PBIO via Websites and Email in exchange for one thousand five hundred dollars. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Pressure Biosciences has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.